These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 66987)

  • 1. Macrophage processing of antigen for induction of tumor immunity.
    Brunda MJ; Raffel S
    Cancer Res; 1977 Jun; 37(6):1838-44. PubMed ID: 66987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Shimizu J; Suda T; Yoshioka T; Kosugi A; Fujiwara H; Hamaoka T
    J Immunol; 1989 Feb; 142(3):1053-9. PubMed ID: 2464022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to virus-free syngeneic tumor cell transplantation in the BALB/c mouse after immunization with homologous tumor cells infected with type C virus.
    Al-Ghazzouli IK; Donahoe RM; Huang KY; Sass B; Peters RL; Kelloff GJ
    J Immunol; 1976 Dec; 117(6):2239-48. PubMed ID: 186539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting effects of activated and nonactivated macrophages and macrophages from tumor-bearing mice on tumor growth in vivo.
    Gabizon A; Leibovich SJ; Goldman R
    J Natl Cancer Inst; 1980 Nov; 65(5):913-20. PubMed ID: 6933261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective serum effects in tumor immunity.
    Vaage J
    Isr J Med Sci; 1976; 12(4-5):334-43. PubMed ID: 939693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro studies on the cellular immune response of tumor-bearing mice to SV40-transformed cells.
    Blasecki JW; Tevethia SS
    J Immunol; 1975 Jan; 114(1 Pt 1):244-9. PubMed ID: 163278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of poly I:C-activated peritoneal cells on the take of transplantable murine tumours.
    Minárovits J; Karczag E; Földes I
    Acta Microbiol Hung; 1987; 34(3-4):197-205. PubMed ID: 3129897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A time factor in the success or failure of immune rejection of transplanted tumors.
    Vaage J
    Cancer Res; 1977 Apr; 37(4):1064-7. PubMed ID: 844038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.
    Hostetler LW; Romerdahl CA; Kripke ML
    Cancer Res; 1989 Mar; 49(5):1207-13. PubMed ID: 2465081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts.
    Shimizu J; Zou JP; Ikegame K; Katagiri T; Fujiwara H; Hamaoka T
    J Immunol; 1991 Mar; 146(5):1708-14. PubMed ID: 1993850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Destruction of experimental malignant melanoma by mediators of cellular immunity.
    Youdim S
    Cancer Res; 1977 Feb; 37(2):572-7. PubMed ID: 401681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific enhancement of tumor growth and depression of cell-mediated immunity following sensitization to soluble tumor antigens.
    Rao VS; Bonavida B
    Cancer Res; 1976 Apr; 36(4):1384-91. PubMed ID: 56998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune RNA-mediated transfer of tumor antigen responsiveness to unresponsive peritoneal exudate cells from tumor-bearing animals.
    Braun DP; Dray S
    Cancer Res; 1977 Nov; 37(11):4138-44. PubMed ID: 908048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Hamaoka T; Shimizu J; Suda T; Fujiwara H
    Princess Takamatsu Symp; 1988; 19():265-75. PubMed ID: 3269360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity to progressive tumors can be induced by antigen presented on regressor tumors.
    Flood PM; Schreiber H; Ron Y
    J Immunol; 1987 May; 138(10):3573-9. PubMed ID: 3571978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.
    Fogler WE; Fidler IJ
    Cancer Res; 1985 Jan; 45(1):14-8. PubMed ID: 3855280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.